New screening recommendations for critical congenital heart defects
In December 2024, the American Academy of Pediatrics published an updated screening algorithm for critical congenital heart defects (CCHD). According…
Cardiovascular
-
-
Sequana Medical’s DSR 2.0 outperforms traditional peritoneal dialysis solutions in study
Following positive data reported earlier this year from a Phase I/II trial, Sequana Medical has touted results from a study…
-
Work-related stress connected to poorer cardiac health
According to a 2023 survey by the American Psychiatric Association, work-related stress affects approximately 77% of the US working population.…
-
AHA 2024: GLP-1R agonist associated with better clinical outcomes in heart failure and CKD
On November 18, at the American Heart Association (AHA) 100th Annual Meeting 2024, the safety of glucagon-like peptide-1 receptor (GLP-1R)…
-
Boston Scientific resumes enrolment in pulsed field ablation trial
Boston Scientific has resumed enrolment for its AVANT GUARD clinical trial, after it was paused in October 2024to “assess a…
-
Penumbra reveals positive data for algorithm-assisted thrombectomy tech
Penumbra has posted positive data for its computer-assisted vacuum thrombectomy (CAVT) technology aimed at treating patients with intermediate-risk pulmonary embolism…
-
Abbott touts long-term efficacy for dissolvable Esprit BTK stent
Abbott has unveiled positive long-term data for its Esprit below-the-knee (BTK) stent in treating the most severe form of peripheral…
-
J&J’s Shockwave deal pays off as IVL catheter meets primary endpoint in trial
Johnson & Johnson’s (J&J) Shockwave Medical unit has reported that its Javelin peripheral intravascular lithotripsy (IVL) catheter system successfully met…
-
Abbott starts new trial to assess early use benefit of HeartMate 3
Abbott has launched a “first-of-its-kind” trial to identify advanced heart failure patients who could potentially benefit from early advanced therapy…
-
Oral GLP-1 receptor agonist Rybelsus reduces risk of cardiovascular events in type 2 diabetes patients
On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral glucagon-like peptide-1 receptor (GLP-1R) agonist,…
